u/FatAspirations

2 theses · first seen Oct 20, 2026

Window	Theses	Resolved	Wins	Win rate	Avg return	Median return
1d	2	2	1	50%	+9.0%	+9.0%
3d	2	2	2	100%	+17.5%	+17.5%
1w	2	2	1	50%	+19.0%	+19.0%
1m	2	2	1	50%	+8.0%	+8.0%
3m	2	2	0	0%	-19.8%	-19.8%
6m	2	2	0	0%	-42.3%	-42.3%
1y	2	2	0	0%	-75.5%	-75.5%

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$ATOSr/pennystocksSuspicious Replies/Awardsbullish

u/FatAspirations · 1962d ago1 prior · 0% at 3mo

Long ATOS

ATOS (DD) Gamma Storm pt 2 - Ticking Time Bomb

ATOS will experience significant forced buying from R2K index funds (10-20M shares on June 25) combined with an extraordinary gamma squeeze from 499K July call contracts representing 23% of shares outstanding. Catalysts include institutional accumulation, options-driven MM buying into July expiry, short covering, and fundamental updates on the Endoxifen drug program, all expected to drive substantial upside.

At post $88.35Now $2.33-97.4% since postedas of Nov 3, 4:45 PM ET

1d+19.2%

3d+34.5%

1w+40.1%

1m-28.0%

3m-39.2%

6m-66.6%

1y-82.3%

original post →

$ATOSr/pennystocksSuspicious Replies/Awardsbullish

u/FatAspirations · 1997d ago1 prior · 0% at 3mo

“largely out of [Redacted Retail Meme Stock] and growing a position in ATOS”

ATOS (DD) - The Next Gamma Storm

ATOS is a biotech with asymmetric upside similar to meme stocks: $138M in cash (no debt, runway to 2024), trades at $1.78/share ex-cash, and will cross the $1B market cap threshold at ~$8.50/share, triggering passive buying and institutional inclusion. With Endoxifen targeting 68% of breast cancers, long-term valuations of $33–$175/share are possible; gamma and short squeeze dynamics add near-term catalysts.

At post $48.45Now $2.33-95.2% since postedas of Nov 3, 4:45 PM ET

1d-1.2%

3d+0.6%

1w-2.2%

1m+44.0%

3m-0.3%

6m-18.0%

1y-68.7%

original post →

End of results.